Newsroom – SyneuRx

Press Release

July 25, 2022

Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board

Apr 13, 2022

SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)

Jan 6, 2022

SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants

Nov 19, 2021

SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing

Jun 23, 2021

SyneuRx Announces Closing of Public Offering

Jun 08, 2021

Taiwan FDA Approves SyneuRx’s IND Application for COVID-19 Clinical Trial

Publication

July 13, 2022

SyneuRx Publishes a Research Paper in《Journal of Alzheimer's Disease Reports》and Presents Disease-modifying Medication Results of Lithium Benzoate, Demonstrated as a Safe and Effective Drug Candidate for Alzheimer's Disease or other Neurodegenerative Disorders. (Accepted)

May 16, 2022

SyneuRx Publishes a Research Paper in《ACS Pharmacology & Translation Science》and Presents Pan-coronal Antiviral Therapeutic Research Results of Pentarlandir®, Demonstrated as a Safe and Effective Drug Candidate.

Media

July 05, 2022

I’m a Virus Expert and It’s Still Dangerous to Go Here

Jun 27, 2022

Here's What Monkeypox Infection Looks Like, Says Doctor
Monkeypox is a rare disease, so far, but cases have been rising.

May 27, 2022

Virus Expert Says Be Ready for This to Happen Next
A new big wave of infection is coming to the U.S.

May 15, 2022

New York Post quoted Emil and mentioned Synapsinae and Neuserine in its article “Hope on the Horizon,” about new treatments for depression

Mar 30, 2022

Q&A with SyneuRx Chief Scientist and CEO., Emil Tsai, M.D.–Ph.D., M.A.S.: What are the top Symptoms of the BA.2 Variant and is it a Major Cause for Concern?